First Wave BioPharma announces second patient dosed in Phase 2 SPAN trial

First Wave BioPharma announced that the second patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The three U.S. clinical trial sites participating in the trial are now actively screening and enrolling patients. "Early indications from our investigators suggest there is an enthusiasm among CF patients about the opportunity to participate in the Phase 2 SPAN clinical trial given the need for improved therapeutic options to treat their EPI," said James Sapirstein, President and CEO of First Wave BioPharma. "We are encouraged by the current pace of enrollment and continue to target a topline data readout from the Phase 2 SPAN trial by mid-2023, which we hope will be a first step towards providing patients with a safe and effective therapy that allows individuals with CF to gain control over EPI, while diminishing the daily pill burden required with porcine-derived pancreatic enzyme replacement therapy."